BioVersys AG’s Post

🎄 Countdown to Knowledge: Scientific Advent Calendar! 🎄 It’s time to reveal today’s answer and explore the fascinating explanation behind it! 🧠✨ Join us daily for more questions that challenge your curiosity and ignite your scientific spirit. Don’t forget to share your guesses and test your knowledge! 🎁 #ScienceFun #AdventCalendar #CuriosityUnlocked #STEM #COSBI #DrugDiscovery #PrecisionMedicine #SingleCellRNASeq #Biotechnology #PharmaceuticalResearch #GeneExpression #MedicalInnovation #TargetedTherapies #LifeSciences #RNASequencing

📡 #BioVersys delivers more impressive news in 2024: announcing last patient, last visit in the Phase 2 clinical trial with its lead asset BV100 and provides a business update. 🎯 Following hot on the heals of the, -  strategic investment by #GIBF in September and launch of BV100 clinical program in China, and -    completion of Phase 2a for alpibectir, BioVersys’ anti-TB molecule that showed PoC in TB patients earlier this year;   🚀 BioVersys is delighted that BV100 has also successfully completed its Phase 2 trial in ventilator associated bacterial pneumonia patients with strong first signs of efficacy. 🚑🛌   🌟 BV100 has the potential to address a large worldwide unmet medical need of patients with Carbapenem-Resistant Acinetobacter baumannii (CRAB) infections, that have limited treatment options. 🌍 🏥 Read the full press release here: https://lnkd.in/d5mS89Yt #SavingLivesinResistantTimes #HealthcareInnovation #antibiotics #AMR #investment #biotech #Europe #China 

📣 Open Call for Hit to Lead programmes ENABLE-2 is still accepting Expressions of Interest: 👉 https://lnkd.in/dxZ9r-Ew 📅 The call is open continuously but to be considered for entry at the next Portfolio Management Committee meeting in October 2024, applications should reach us by 3 September 2024. Please visit the website (https://lnkd.in/dAxf2P5D) for more information about ENABLE-2 and instructions on how to submit an Expression of Interest. 🔹 ENABLE-2 is an antibacterial drug discovery platform focused on the early stages of antibiotic discovery. Platform partners: Uppsala universitet, SciLifeLab, RISE Research Institutes of Sweden, Statens Serum Institut, Latvian Institute of Organic Synthesis 🔹 Vetenskapsrådet / Swedish Research Council has been commissioned by the Swedish Government to support the ENABLE-2 platform #antimicrobialresistance #antibioticresistance #antibiotics #amr

📣 ENABLE-2 Incubator Open Call ➡ Hit Identification and Validation The ENABLE-2 platform offers evaluation of the antibiotic potential of novel compounds. 🔹 Read more here and send us your Expression of Interest https://lnkd.in/d27wU4KZ 🔹 The call is open continuously. Expressions of Interest submitted by 31 October 2024 will be evaluated by end of November 2024. ENABLE-2 is an antibacterial drug discovery platform focused on the early stages of antibiotic discovery. Platform partners: Uppsala universitet, SciLifeLab, RISE Research Institutes of Sweden, Statens Serum Institut, Latvian Institute of Organic Synthesis Vetenskapsrådet / Swedish Research Council has been commissioned by the Swedish Government to support the ENABLE-2 platform #antimicrobialresistance #antibioticresistance #antibiotics #amr

Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting To learn more, please visit: https://ow.ly/kqpN50SqOz8 $ENSC #biosciences #nextgenerationopioids

💡 CMTx Biotech, Inc. wins $299,993 award from Department of Health and Human Services, National Institutes of Health! 🎉 🔬 The award is for a novel host-directed therapeutic for the treatment of sulfur mustard induced lung injury. CMTX Biotech is working to commercialize a pipeline of proprietary non-antibiotic chemically-modified tetracycline compositions and formulations for the host-modulatory treatment of diseases with high unmet needs. 🌟 📊 This is a project grant (B) award, categorized under Assistance Prime Transaction, and it will last for 1.92 years, starting from July 9, 2024, and ending on June 30, 2026. The research type is Grant/Subgrant/Subcontract. #SBIR #STTR #CMTXBiotech #DHHS #NIH #Innovation #Research #Awards

Breaking barriers with unexpected discoveries—this is worth a read... HAPPY FRIDAY!!! A recent patent application revealed something we at Advanced Instruments, LLC are incredibly proud of 🙌🏻: Our InstiGRO™ supplement, part of Advanced Instruments’ Solentim portfolio, played a pivotal role in advancing rAAV production using HeLaS3 cells.   Here’s what stood out: ✅ In single-cell cloning, InstiGRO provided critical support for colony growth and viability. ✅ It helped researchers push the boundaries of what HeLa cells could achieve in this context. ✅ The result? Improved doubling times, higher productivity, and a workflow for scalable rAAV production.   What’s most exciting is this: Our customers’ curiosity and confidence in the product uncovered new possibilities! 💪🏻   To the scientists challenging the status quo: Keep pushing. The breakthroughs you make today might inspire the next wave of innovation tomorrow.   👉🏻 Interested in a Free Sample !? https://lnkd.in/emGwEX46 🔗 Read the full patent application here: https://lnkd.in/eSqpnJ5T   🌐 To learn more about Solentim’s cell culture supplements: https://lnkd.in/e8D5cQ4h #CellLineDevelopment #Biopharma #Biotechnology #Innovation #GeneTherapy

Working on HeLa cells? Take a moment to check out this post—we’ve got insights that might be just what you’re looking for!

Review paper out today by one of the scientific co-founders of Thymofox, an Apollo Health Ventures portfolio company focused on thymus regeneration with small molecule medicines. Give a read! Jarrod Dudakov #thymus #biotechnology #lifescience #regenerativemedicine

You may have heard about the different tiered options that we offer for various #DrugInteractions and #DrugMetabolism studies, but do you know which is most appropriate for your specific goals and stage of development? Read our newest blog to understand the differences between the tiers and see which is right for your program: <<https://lnkd.in/gPb3rfRR>> #DrugDevelopment #ADME #DMPK #Bioanalysis